PD

PDS Biotechnology CorpNASDAQ PDSB Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.115

Micro

Exchange

XNAS - Nasdaq

PDSB Stock Analysis

PD

Uncovered

PDS Biotechnology Corp is uncovered by Eyestock quantitative analysis.

Market cap $B

0.115

Dividend yield

Shares outstanding

28.509 B

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Florham Park, New Jersey and currently employs 22 full-time employees. The company went IPO on 2015-10-01. The firm is engaged in the developing a pipeline of molecularly targeted immunotherapies. The firm owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. The company develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.

View Section: Eyestock Rating